Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 17 April 2026Expected publication date: 7 May 2026
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)Status:In developmentProgramme:Health technology evaluationExpected publication date: 2 December 2026
Optical Coherence Tomography to guide percutaneous coronary interventionStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC